UK Markets close in 2 hrs 43 mins

  • FTSE 100

    6,689.06
    +50.21 (+0.76%)
     

  • FTSE 250

    20,510.19
    +159.78 (+0.79%)
     

  • AIM

    1,195.23
    -3.33 (-0.28%)
     

  • GBP/EUR

    1.1276
    +0.0017 (+0.15%)
     

  • GBP/USD

    1.3708
    +0.0032 (+0.2372%)
     

  • BTC-GBP

    23,101.15
    -1,537.48 (-6.24%)
     

  • CMC Crypto 200

    636.96
    -10.37 (-1.60%)
     

  • S&P 500

    3,855.36
    +13.89 (+0.36%)
     

  • DOW

    30,960.00
    -36.98 (-0.12%)
     

  • CRUDE OIL

    52.91
    +0.14 (+0.27%)
     

  • GOLD FUTURES

    1,857.80
    +2.60 (+0.14%)
     

  • NIKKEI 225

    28,546.18
    -276.11 (-0.96%)
     

  • HANG SENG

    29,391.26
    -767.75 (-2.55%)
     

  • DAX

    13,890.82
    +246.87 (+1.81%)
     

  • CAC 40

    5,540.15
    +67.79 (+1.24%)
     
COVID-19:

UK economy hangs in balance amid EU vaccine row

The EU said companies will have to provide more information when they export vaccines, which could hit UK supplies

Gilead holds 25.54% of Galapagos shares

Galapagos NV
·2-min read

Mechelen, Belgium; 11 January 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.

Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 6 January 2021 from Gilead Sciences, Inc., who notified a change in the chain of intermediary companies through which Gilead holds its shares in Galapagos. The change in the chain of intermediary companies is the result of an internal reorganization as a result of which Gilead holds its shares in Galapagos as of 31 December 2020 through its direct subsidiary Gilead Biopharmaceutics US, LLC, which through Gilead Sciences Ireland UC controls Gilead Therapeutics A1 Unlimited Company, which in turn holds 16,707,477 of Galapagos' voting rights, consisting of 16,707,477 shares (unchanged). Those 16,707,477 shares represent 25.54% of Galapagos' currently outstanding 65,411,767 shares.

The full transparency notification is available on the Galapagos website.

About Galapagos
Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
ir@glpg.com

Media:
Carmen Vroonen
Global Head Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900
communications@glpg.com

1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.



Attachment


Latest stories

  • Itron to Improve Water Efficiency and Reduce Water Losses in Moldova

    Floresti Communal Services to deploy Itron's Water Operations Management (WOM) solution, wide-area low-power network and water meters.

  • Global Apparel and Leather Products Market (2021 to 2030) - COVID-19 Impact and Recovery - ResearchAndMarkets.com

    The "Apparel and Leather Products Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

  • Omeros Hires Nadia Dac as Chief Commercial Officer

    Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial launch of narsoplimab, the company’s mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor. A Biologics License Application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy is under Priority Review by U.S. Food and Drug Administration. Ms. Dac will also be responsible for driving continued sales growth of Omeros’ commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution 1%/0.3%), the only drug of its kind approved for use during cataract and lens replacement surgery.

  • CHSI Technologies Continues Delivering on Business Momentum and Product Innovation with Record Growth Numbers in 2020

    CHSI Technologies ("CHSI" or the "Company"), the market-leading SaaS InsureTech firm for policy and claims lifecycle management, billing, decision support and analytics announced record financial results and exponential sales growth in 2020. Post CHSI’s majority recapitalization in Q4 2019 by Bow River Capital’s SaaS Growth Equity Fund, CHSI executed on its strategic vision and operating plan; highlighted by releasing modern SaaS Claims and Portal modules, aggressively scaling each business unit, and re-engineering the Company’s go-to-market engine.

  • Violent clashes as Indian farmers storm Delhi's Red Fort

    Violent clashes as Indian farmers storm Delhi's Red Fort. Farmers protesting against new agriculture laws enter grounds of historic fort as violence breaks out

  • Vaccines minister ‘confident’ in supply of Pfizer jab from Europe

    Nadhim Zahawi said the UK’s vaccination programme is on track and refuted claims the AstraZeneca vaccine was not effective in older people.

  • 'A huge loss': tributes to victims of the UK's Covid second wave

    'A huge loss': tributes to victims of the UK's Covid second wave. Stories of a 10-year-old and a 102-year-old, a heart doctor, a kebab shop partner and a Santa

  • Net Asset Value(s)

    WisdomTree Issuer plc – Daily Fund Prices 25-January-21 WisdomTree Artificial Intelligence UCITS ETF - USD Acc25/01/2021IE00BDVPNG135418541USD368,071,850.4067.9282WisdomTree AT1 CoCo Bond UCITS ETF – USD25/01/2021IE00BZ0XVF52513029USD53,111,173.13103.5247WisdomTree AT1 CoCo Bond UCITS ETF – EUR Hedged25/01/2021IE00BFNNN236279036EUR28,734,682.09102.9784WisdomTree AT1 CoCo Bond UCITS ETF – GBP Hedged25/01/2021IE00BFNNN45934640GBP3,613,644.13104.32WisdomTree AT1 CoCo Bond UCITS ETF – USD Acc25/01/2021IE00BZ0XVG6942463USD5,097,911.84120.0554WisdomTree AT1 CoCo Bond UCITS ETF – USD Hedged25/01/2021IE00BFNNN01217006USD1,862,516.13109.5211WisdomTree Battery Solutions UCITS ETF - USD Acc25/01/2021IE00BKLF1R755903534USD294,104,380.6049.8184WisdomTree Cloud Computing UCITS ETF - USD Acc25/01/2021IE00BJGWQN7211424000USD625,016,705.3054.7108WisdomTree Cybersecurity UCITS ETF - USD Acc25/01/2021IE00BLPK357740000USD990,271.1924.7568WisdomTree Emerging Markets Equity Income UCITS ETF25/01/2021IE00BQQ3Q0672583191USD38,736,185.4414.9955WisdomTree Emerging Markets Equity Income UCITS ETF Acc25/01/2021IE00BDF12W49190558USD4,062,331.5021.3181WisdomTree Emerging Markets Small Cap Dividend UCITS ETF25/01/2021IE00BQZJBM261630000USD30,163,025.5918.5049WisdomTree Enhanced Commodity UCITS ETF – CHF Hedged Acc25/01/2021IE00BG88WL21185000CHF1,920,563.6310.3814WisdomTree Enhanced Commodity UCITS ETF – EUR Hedged Acc25/01/2021IE00BG88WG771700000EUR16,476,449.309.692WisdomTree Enhanced Commodity UCITS ETF – GBP Hedged Acc25/01/2021IE00BG88WH841175000GBP11,602,422.379.8744WisdomTree Enhanced Commodity UCITS ETF - USD25/01/2021IE00BZ1GHD37575000USD6,032,917.4010.492WisdomTree Enhanced Commodity UCITS ETF - USD Acc25/01/2021IE00BYMLZY747925000USD86,557,376.3910.9221WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR25/01/2021IE00BD49R912210439EUR11,671,440.0655.4623WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR Acc25/01/2021IE00BD49RB3959498EUR3,376,779.0656.7545WisdomTree EUR Government Bond Enhanced Yield UCITS ETF25/01/2021IE00BD49RJ1519908EUR1,127,756.6356.6484WisdomTree EUR Government Bond Enhanced Yield UCITS ETF – EUR Acc25/01/2021IE00BD49RK2040000EUR2,319,139.1057.9785WisdomTree Europe Equity Income UCITS ETF25/01/2021IE00BQZJBX311732717EUR18,451,010.7810.6486WisdomTree Europe Equity Income UCITS ETF Acc25/01/2021IE00BDF16007352386EUR4,751,457.9913.4837WisdomTree Europe Equity UCITS ETF - CHF Hedged Acc25/01/2021IE00BYQCZT117703CHF136,580.5117.7308WisdomTree Europe Equity UCITS ETF - EUR Acc25/01/2021IE00BYQCZX56269545EUR4,872,600.7118.0771WisdomTree Europe Equity UCITS ETF - GBP Hedged25/01/2021IE00BYQCZQ89131454GBP1,488,132.8011.3206WisdomTree Europe Equity UCITS ETF - USD Hedged25/01/2021IE00BVXBH1631100046USD20,692,201.2818.8103WisdomTree Europe Equity UCITS ETF - USD Hedged Acc25/01/2021IE00BYQCZP722048673USD45,441,317.7922.1809WisdomTree Europe Small Cap Dividend UCITS ETF25/01/2021IE00BQZJC5271609262EUR27,386,164.3017.0178WisdomTree Europe Small Cap Dividend UCITS ETF Acc25/01/2021IE00BDF16114262191EUR4,131,834.0515.7589WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR25/01/2021IE00BZ56SY76630208EUR11,094,910.7917.6052WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR Acc25/01/2021IE00BZ56TQ67679042EUR13,679,873.0320.1458WisdomTree Global Quality Dividend Growth UCITS ETF - USD25/01/2021IE00BZ56RN96308660USD8,691,290.5428.1581WisdomTree Global Quality Dividend Growth UCITS ETF - USD Acc25/01/2021IE00BZ56SW521750284USD53,529,448.9830.5833WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc25/01/2021IE00BYQCZL35235650CHF4,630,608.1019.6504WisdomTree Japan Equity UCITS ETF - EUR Hedged Acc25/01/2021IE00BYQCZJ13201551EUR3,390,263.5316.8209WisdomTree Japan Equity UCITS ETF - GBP Hedged25/01/2021IE00BYQCZF7489539GBP967,177.8710.8017WisdomTree Japan Equity UCITS ETF - JPY Acc25/01/2021IE00BYQCZN58189960USD4,253,519.8222.3917WisdomTree Japan Equity UCITS ETF - USD Hedged25/01/2021IE00BVXC48541451738USD24,806,233.3317.0873WisdomTree Japan Equity UCITS ETF - USD Hedged Acc25/01/2021IE00BYQCZD50400818USD7,858,919.5819.6072WisdomTree UK Equity Income UCITS ETF25/01/2021IE00BYPGTJ261800000GBP7,632,764.854.2404WisdomTree US Equity Income UCITS ETF25/01/2021IE00BQZJBQ63804894USD15,397,633.5519.13WisdomTree US Equity Income UCITS ETF - EUR Hedged Acc25/01/2021IE00BD6RZW238073EUR135,996.3016.8458WisdomTree US Equity Income UCITS ETF - GBP Hedged Acc25/01/2021IE00BD6RZZ53379189GBP5,738,418.9215.1334WisdomTree US Equity Income UCITS ETF Acc25/01/2021IE00BD6RZT931455101USD29,698,530.9720.4099WisdomTree US Quality Dividend Growth UCITS ETF - USD25/01/2021IE00BZ56RD98436031USD12,287,067.1428.1793WisdomTree US Quality Dividend Growth UCITS ETF - USD Acc25/01/2021IE00BZ56RG201947843USD59,166,970.7530.3756WisdomTree USD Floating Rate Treasury Bond UCITS ETF - USD25/01/2021IE00BJFN5P6326000USD1,304,061.9950.1562WisdomTree USD Floating Rate Treasury Bond UCITS ETF - USD Acc25/01/2021IE00BJJYYX67353822USD18,045,573.0351.0018

  • Viable rape prosecutions ‘dropped thanks to CPS conviction target’, campaigners tell High Court

    Viable rape prosecutions were abandoned by the CPS after a change in approach to try to secure a higher conviction rate, campaigners told the High Court today. The Centre for Women’s Justice (CWJ) and End Violence Against Women (EVAW) coalition claims prosecutors were left in a “mess” when a target of convictions in 60 per cent of rape cases was introduced in 2016.

  • Insights on the Sputtering Equipment Global Market to 2027 - Featuring Applies Materials, Canon & Intevac Among Others

    Dublin, Jan. 26, 2021 (GLOBE NEWSWIRE) -- The "Sputtering Equipment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. The publisher brings years of research experience to the 5th edition of this report. The 190-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Global Sputtering Equipment Market to Reach $2.3 Billion by 2027Amid the COVID-19 crisis, the global market for Sputtering Equipment estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$2.3 Billion by 2027, growing at a CAGR of 3.5% over the analysis period 2020-2027. Semiconductor, one of the segments analyzed in the report, is projected to record a 3.3% CAGR and reach US$826.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Solar Energy segment is readjusted to a revised 4% CAGR for the next 7-year period.The U.S. Market is Estimated at $490.5 Million, While China is Forecast to Grow at 6.2% CAGRThe Sputtering Equipment market in the U.S. is estimated at US$490.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$478.7 Million by the year 2027 trailing a CAGR of 6.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.Display Segment to Record 4.3% CAGRIn the global Display segment, USA, Canada, Japan, China and Europe will drive the 3.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$274.4 Million in the year 2020 will reach a projected size of US$355.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$323.1 Million by the year 2027, while Latin America will expand at a 5.3% CAGR through the analysis period. Competitors identified in this market include, among others: Applied Materials, Inc.Canon, Inc.Intevac, Inc.Singulus Technologies AGUlvac GmbH Key Topics Covered: I. INTRODUCTION, METHODOLOGY & REPORT SCOPEII. EXECUTIVE SUMMARY1. MARKET OVERVIEW Global Competitor Market SharesSputtering Equipment Competitor Market Share Scenario Worldwide (in %): 2019 & 2025Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVEIII. MARKET ANALYSISIV. COMPETITION Total Companies Profiled: 43 For more information about this report visit https://www.researchandmarkets.com/r/133sxz Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Adenosine Triphosphate Swab Test Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type and Application and Geography

    The global adenosine triphosphate (ATP) swab test market is expected to reach US$ 369. 71 million by 2027 from US$ 198. 21 million in 2019; the market is estimated to grow at a CAGR of 8. 2% from 2020 to 2027.New York, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Adenosine Triphosphate Swab Test Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type and Application and Geography" - https://www.reportlinker.com/p06010018/?utm_source=GNW The growth of the adenosine triphosphate (ATP) swab test market is mainly attributed to the globally rising prevalence of healthcare-associated infections and increasing emphasis on food safety. However, limitations associated with the ATP swab tests are likely to hamper the growth of the market to a certain extent.The utilization of adenosine triphosphate is a major indicator of cleanliness and sterilization in food & beverages.Rising incidence of foodborne diseases and food contamination is prominently expected to drive the ATP swab test market during the forecast period.According to data published by the World Health Organization (WHO) estimated that 600 million new cases that is one in ten people across the globe will fall ill due to contaminated food.Moreover, according to the estimates by the WHO, 1 in 10 people fall ill owing to consumption of unsafe food.In addition, data published by Center for Science and Environment in July 2020 stated that foodborne diarrhea and contaminated water cause deaths of around 700,000 people in Southeast Asia each year. Further, as per data given by the Union Health Ministry of India, out of 1,649 disease outbreaks in India during 2017, around 242 outbreaks were related to the contaminated food and water.Such substantial prevalence of foodborne diseases and conditions is boosting the need for food safety. This need is likely to drive the ATP swab test market during the forecast period.Based on type, the adenosine triphosphate (ATP) swab test market is segmented into free ATP test and microbial ATP test.In 2019, the microbial ATP test segment held the largest share of the market.The same segment is expected to grow at the faster rate during the coming year.Based on application, the market was segmented into pharmaceutical and biotechnology companies, food and beverage companies, hospitals and diagnostics laboratories, and academic and research institutions.In 2019, the pharmaceutical and biotechnology company segment held the largest share of the market. Increasing number of pharmaceutical and biopharmaceutical companies and rising demand for sanitization are expected to drive the segment over the forecast period.World Health Organization, National Health Service, Centers for Disease Control and Prevention, American Society of Testing and Material, and Saudi Forum for Hospital Sterilization Services, along with company websites, are the major primary and secondary sources cited while preparing this report.Read the full report: https://www.reportlinker.com/p06010018/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Lost episodes ranked from worst to best

    As the US TV drama's finale turns 10, Jacob Stolworthy goes back through every single twist, turn and big moment

  • Covid: Former Australia PM Tony Abbott rants about ‘virus hysteria’

    Travel restrictions amount to health ‘despotism’, claims ex-PM

  • Bright Power Leaders Join Boards of Northeast Sustainable Energy Association (NESEA) and New York Passive House (NYPH)

    Andrea Mancino and Carmel Pratt were elected to the Boards of Directors for two organizations driving sustainable buildings and industry education.

  • Netherlands shaken by third night of riots over Covid curfew

    Netherlands shaken by third night of riots over Covid curfew. About 150 anti-lockdown protesters arrested after shops looted and cars set alight in several towns and cities

  • Living in the UK: have you booked a holiday after being vaccinated?

    Living in the UK: have you booked a holiday after being vaccinated?. We would like to hear from older people who have been vaccinated and are thinking of going on holiday abroad

  • Quarantine hotels set to be introduced to limit spread of coronavirus variants

    Vaccines Minister Nadhim Zahawi said an announcement on the plans would be made later.

  • Better Buy: MercadoLibre vs. Amazon

    This played to the sweet spots of two e-commerce leaders: retail giant Amazon (NASDAQ: AMZN) and Latin America's largest online retailer, MercadoLibre (NASDAQ: MELI). Amazon's five-year head start on MercadoLibre and its faster growth has put the e-commerce juggernaut into the select $1 trillion-plus market capitalization club.

  • Why experts say there is no basis to claims in Germany about efficacy of AstraZeneca vaccine

    Why experts say there is no basis to claims in Germany about efficacy of AstraZeneca vaccineAnalysis: Drug company and scientific partners at Oxford University have strongly pushed back against German press report * Coronavirus – latest updates * See all our coronavirus coverage

  • Modest Hatton reaches new heights in burgeoning golf career

    Tyrrell Hatton found it surreal when he looked at golf’s world ranking and saw himself at a career-high No. 5, above the likes of Rory McIlroy, Bryson DeChambeau and Brooks Koepka. A golfer once best known for his loud and often self-deprecating outbursts on the course is now better regarded as a proven winner on the European Tour. The latest big victory in the 29-year-old Hatton’s burgeoning career came in Abu Dhabi last week, when he outplayed McIlroy in the final round to win by four shots and claim a sixth title on the European Tour.